181 related articles for article (PubMed ID: 35773413)
21. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis.
Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY
Nature; 2013 Jan; 493(7431):236-40. PubMed ID: 23201680
[TBL] [Abstract][Full Text] [Related]
22. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
[TBL] [Abstract][Full Text] [Related]
23. SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
Bilir B; Osunkoya AO; Wiles WG; Sannigrahi S; Lefebvre V; Metzger D; Spyropoulos DD; Martin WD; Moreno CS
Cancer Res; 2016 Mar; 76(5):1112-21. PubMed ID: 26701805
[TBL] [Abstract][Full Text] [Related]
24. In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
Riedel M; Berthelsen MF; Cai H; Haldrup J; Borre M; Paludan SR; Hager H; Vendelbo MH; Wagner EF; Bakiri L; Thomsen MK
Oncogene; 2021 Apr; 40(13):2437-2447. PubMed ID: 33674748
[TBL] [Abstract][Full Text] [Related]
25. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms.
Li C; Zheng X; Li W; Bai F; Lyu J; Meng QH
BMC Cancer; 2018 Jan; 18(1):61. PubMed ID: 29316891
[TBL] [Abstract][Full Text] [Related]
26. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
27. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
[TBL] [Abstract][Full Text] [Related]
28. Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.
Berger PL; Frank SB; Schulz VV; Nollet EA; Edick MJ; Holly B; Chang TT; Hostetter G; Kim S; Miranti CK
Cancer Res; 2014 Jun; 74(12):3357-68. PubMed ID: 24762396
[TBL] [Abstract][Full Text] [Related]
29. Plectin is a regulator of prostate cancer growth and metastasis.
Buckup M; Rice MA; Hsu EC; Garcia-Marques F; Liu S; Aslan M; Bermudez A; Huang J; Pitteri SJ; Stoyanova T
Oncogene; 2021 Jan; 40(3):663-676. PubMed ID: 33219316
[TBL] [Abstract][Full Text] [Related]
30. Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Nikhil K; Kamra M; Raza A; Shah K
Cancer Lett; 2021 Feb; 498():1-18. PubMed ID: 32931887
[TBL] [Abstract][Full Text] [Related]
31. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
32. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
33. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
[TBL] [Abstract][Full Text] [Related]
35. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.
Liu J; Muturi HT; Khuder SS; Helal RA; Ghadieh HE; Ramakrishnan SK; Kaw MK; Lester SG; Al-Khudhair A; Conran PB; Chin KV; Gatto-Weis C; Najjar SM
Metabolism; 2020 Jun; 107():154215. PubMed ID: 32209360
[TBL] [Abstract][Full Text] [Related]
36. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
Xi Y; Chen Y
J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.
Rodriguez M; Siwko S; Zeng L; Li J; Yi Z; Liu M
Oncogene; 2016 Mar; 35(9):1153-62. PubMed ID: 26028029
[TBL] [Abstract][Full Text] [Related]
39. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
40. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
